Portugal - Re-Imbursed Pharmaceutical Market
Since 2014, Portugal Re-Imbursed Pharmaceutical Market increased 0.7points year on year. With 25 Percent of Generics in Value in 2019, the country was ranked number 9 among other countries in Re-Imbursed Pharmaceutical Market. Portugal is overtaken by Slovakia, which was ranked number 8 at 25.2 Percent of Generics in Value and is followed by Spain with 23.6 Percent of Generics in Value. Austria topped the ranking with 52.2 Percent of Generics in Value in 2019, a growth of 2.8points compared to 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark witnessed the best average annual growth at +6.9points per year, while Slovakia recorded the worst performance at -7.8points per year.
Loading...
| Date | Percent of Generics in Value |
|---|---|
| 2019 | 25.00 |
| 2018 | 25.40 |
| 2017 | 24.60 |
| 2016 | 24.60 |
| 2015 | 24.30 |
How does Portugal rank in Re-Imbursed Pharmaceutical Market?
| # | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
| 2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
| 8 |
#8
Slovakia
|
25.20 % | 2019 | -4.2 % | -7.8 % | View data | |
| 9 |
#9
Portugal
|
25.00 % | 2019 | -1.6 % | +0.7 % | View data | |
| 10 |
#10
Spain
|
23.60 % | 2019 | +5.4 % | +1.6 % | View data | |